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Especially during the first year of life,
children are plagued by pathogens jockey-
ing for position at the mucosal surfaces [1].
Respiratory viruses have diverse pathways
to success: influenza is highly infectious and
undergoes rapid evolution to escape pro-
tective immunity, while rhinoviruses suc-
ceed by being so diverse that we are unlikely
to experience all of them in a lifetime. With
both these viruses, reinfection with the
exact same strain is exceptional.
Immune Responses to RSV
Infection
With respiratory syncytial virus (RSV),
however, the situation is curiously different.
RSV shows antigenic variation, but the
weak protective immune response induced
by natural infection wanes rapidly, espe-
cially in the upper respiratory tract. Even
antigenically similar or identical viruses are
able to reinfect with relative ease. How
RSV gets around our immune defences
continues to puzzle immunologists [2].
Although RSV usually causes relatively
trivial common cold symptoms, it can also
have serious and devastating effects in
vulnerable populations. Worldwide, it is a
major source of disease and death in children
under 5 years of age [3] and is increasingly
appreciated as a cause of significant winter
morbidity and mortality amongst elderly
[4,5] and immunocompromised people. In
addition, delaying RSV disease by passive
antibody therapy with antiviral monoclonal
antibodies palivizumab not only prevents
bronchiolitis, but also causes a remarkable
reduction in the frequency of recurrent
wheeze in later childhood [6].
While many infectious diseases can be
prevented by vaccination, over 40 years of
work has failed to produce a vaccine for
RSV disease. The field is now highly active
again, with many vaccine producers seeing
RSV as one of the major large unmet
needs. While on-going investments in
vaccine research raise hope that a vaccine
for RSV might become available in the
next 5 years, it remains unclear what type
of immune response is most protective
against infection, or how to be sure that a
vaccine will not enhance disease.
The Uses of Whole Blood RNA
Analysis
The technique of whole blood RNA
profiling is now well established as a
research tool. The RNA obtained is
predominantly cellular, although serum
does contain small amounts of intact
mRNA and micro (mi)RNA bound to
protein, HDL, or in apoptotic debris [7].
Whole blood RNA profiling is certainly
more than just an expensive blood count:
results depend not only on the number and
type of cells in the blood sample, but also on
the activation state and the exposure of the
cells to stimulatory or inhibitory factors in
the blood or in the tissues through which
the cells have passed. The circulating cells
may represent cells in transit from one site
to another, overspill from tissue inflamma-
tion, or may be cells that have been rejected
by the tissue as irrelevant.
In this context, the recent study by
Asuncion Mejias and colleagues in PLOS
Medicine represents a significant advance in
our understanding of RSV’s special rela-
tionship with the immune system. By
analysing the transcriptional profile from
the blood of children infected with RSV,
influenza, or rhinovirus, the authors aim
to identify biomarkers that both aid in
diagnosis and predict severity. Immunolo-
gists will be especially excited to see gene
clusters changing in ways that correlate
with the nature of the infecting pathogen,
giving clues about pathogenesis and the
protective mechanisms that operate differ-
ently in the response to diverse infections.
What Does It Tell Us about RSV
Disease?
RSV disease can be regarded as a
dysregulated immune response to viral
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Linked Research Article This
Perspective discusses the following
new study published in PLOS
Medicine:
Mejias A, Dimo B, Suarez NM, Garcia
C, Suarez-Arrabal MC, et al. (2013)
Whole Blood Gene Expression Pro-
files to Assess Pathogenesis and
Disease Severity in Infants with
Respiratory Syncytial Virus Infection.
PLoS Med 10(11): e1001549. doi:10.
1371/journal.pmed.1001549.
In this study, Mejias and colleagues
found that specific blood RNA
profiles of infants with RSV LRTI
allowed for specific diagnosis, bet-
ter understanding of disease path-
ogenesis, and better assessment of
disease severity.
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infection [2]. Interestingly, Mejias and
colleagues found that RSV infection was
associated with neutrophil activation (a
cell type known to contribute to RSV
disease [8]), increased markers of inflam-
mation, and upregulation of interferon-
related genes, but with suppression of T
and B cell responses. This pattern was
especially marked in infants aged less than
6 months. Although the transcriptomic
profile was assessed relatively late in
disease (typically 5–6 days after symptom
onset), it still helped anticipate subsequent
outcome.
This study moves the field several steps
towards the clinical use of transcriptomic
profiling in the diagnosis and prognostica-
tion of children with acute respiratory
infections. The finding that innate inflam-
matory genes are upregulated during RSV
infection emphasises the importance of
mucosal inflammation, and fits well with
previous findings from genetic studies that
highlight innate immunity in RSV disease
[9].
The reduction in genes normally asso-
ciated with T and B cells has alternative
interpretations. These cells might be
depleted from peripheral blood because
they are accumulating at the site of
disease; in this case, their absence from
blood demonstrates their importance in
the pathogenesis. Alternatively, it could be
that part of RSV’s evasion strategy is to
inhibit these responses, destroying the cells
that are vital for protection against
reinfection. This second possibility is
supported by studies showing a lack of T
cells in the lungs of children with bron-
chiolitis [10], but this remains controver-
sial.
Another response that is conspicuously
absent is the T-helper 2 pattern (IL-4, IL-
5, IL-13) often associated with asthmatic
or atopic responses. Some studies of the
pulmonary response to RSV indicate an
over expression of such genes and an
increase in Th2 cytokines [11], but no
such signature appears in the studies of
Mejias and colleagues. Here again, the
peripheral blood may not be telling the
whole story and needs to be complement-
ed by detailed studies of the response in
the respiratory tract.
The findings with respect to the activa-
tion of type 1 interferon genes are intrigu-
ing. It has long been known that the non-
structural proteins of RSV, expressed in
great abundance in the earliest phase of
infection, are capable of inhibiting host
interferon responses [12]. However, the
present study shows a significant over-
expression of interferon-related genes, es-
pecially in children with severe illness. It is
important to acknowledge that the children
were only enrolled into the study relatively
late in disease; it will be interesting in future
studies to see which patterns of gene
expression are present earlier in disease,
at a time when viral load may be greatest
and the potential for viral inhibition of
interferon is greater. However, Mejias and
colleagues found that the interferon activa-
tion signal increases still further during
convalescence, raising the possibility that
active virus replication does indeed partial-
ly inhibit interferon responses and that this
inhibition lifts during viral clearance.
What Does the Future Hold?
Although expression profiling of cells in
the peripheral blood has limitations in
terms of monitoring the responses in the
affected tissue, the technique clearly has
great promise for discovering combina-
tions of gene expression that are indicative
of both specific pathogens and also the
future course of disease.
With multiplex testing for combinations
of disease markers that indicate disease
subtypes (or ‘‘endophenotypes’’) becoming
ever more feasible as a near-patient
diagnostic aid, studies such as that by
Mejias and colleagues may give rise to new
and informative tests that help to define
the pathogenesis of disease on an individ-
ual basis and thus dictate clinical manage-
ment. This is especially important in an
era in which many new drugs are
biological agents, targeting specific disease
pathways that may be important in some
patients but not others.
Clinicians will hope that improved
diagnostic accuracy from multiplex tests
arising from broad gene expression screens
will be accompanied by the introduction of
such new treatments. The golden combi-
nation of rational testing linked to specific
treatment should allow avoidance of
expensive or harmful interventions,
streamline the care of vulnerable patients,
and at last provide new ways to treat RSV
disease that go beyond the simply sup-
portive. The study from Mejias and
colleagues is a significant step towards that
long-awaited goal.
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